Eric Kaldjian

MD, Chief Medical Officer

Dr. Eric Kaldjian is Chief Medical Officer at RareCyte. He trained in anatomic pathology at the University of Michigan and subsequently at the National Cancer Institute. His pharmaceutical experience at Hoffmann- La Roche and at Parke-Davis/Pfizer encompassed discovery research through full clinical development positions with a focus on translational medicine. He has directed clinical genomics programs at Gene Logic, was Chief Scientific Officer at Transgenomic, and was Medical Director for Companion Diagnostics at Ventana Medical Systems before joining RareCyte, where he oversees scientific and medical applications of its rare cell detection technology. He is an associate member of the BioInterfaces Institute at the University of Michigan.

Published Pieces by Eric Kaldjian

Delivering on the Promise of Liquid Biopsy

Unter Pathologen (Knowledge Pathway, Knowledge Pathway) , Webinars (Knowledge Pathway, Knowledge Pathway)

The potential for non-invasive tests that provide equivalent research and diagnostic value as can be obtained from tissue biopsies is real, but not yet realized. Tissue biopsies allow for identification, phenotyping and molecular analysis of cancer and...

Delivering on the Promise of Liquid Biopsy

Unter Pathologen (Knowledge Pathway, Knowledge Pathway) , Webinars (Knowledge Pathway, Knowledge Pathway)

Delivering on the Promise of Liquid Biopsy

Unter Pathologen (Knowledge Pathway, Knowledge Pathway) , Webinars (Knowledge Pathway, Knowledge Pathway)